Companion animal oncologic pathology has always been a major part of the veterinary pathology discipline. Providing a correct diagnosis of a neoplastic entity, as well as an accurate prognosis, forms a cornerstone for an effective surgical pathology service. With the emergence of dogs and cats as potential models for human neoplastic diseases, well-characterized companion animal neoplastic disease processes are important. Additionally, as the public expectation of veterinary care becomes comparable with that provided in human medicine, carefully established and uniformly applied criteria to classify neoplastic diseases and prognosticate them become critical. As the science of veterinary oncology advances, the need increases to identify novel prognostic markers associated with metastasis, recurrence, disease-free survival intervals, and overall survival. In addition, as new therapeutic protocols-including cancer vaccines, chemotherapeutics, and radiation therapies-are developed and applied to veterinary patients, the need becomes increasingly evident to discover predictive markers and to identify patients who are likely to respond or not. With the enormous amounts of data being generated in the veterinary community, marked variation among research trials can be recognized in study design, assay performance, and reporting. To address these variations and to allow meta-analyses of studies, the veterinary pathology and oncology community needs to develop standards for study design and reporting of results, including the necessity to perform rigorous controlled experiments to identify and characterize prognostic and therapeutic markers.
The January 2011 issue of Veterinary Pathology focuses on a number of initiatives of the American College of Veterinary Pathologists Oncology Committee to address these issues. The article in this special focus, ''Recommended Guidelines for the Conduct and Evaluation of Prognostic Studies in Veterinary Oncology,'' represents the consensus of an international group of veterinary pathologists and oncologists, and it highlights the importance of close collaboration among veterinary pathologists and oncologists to advance our abilities to diagnose, prognosticate, and successfully treat animal cancer. A number of additional articles in this issue address the current state of the prognostication and diagnosis of neoplastic diseases, including canine melanomas, canine mast cell tumors, canine mammary carcinomas, canine soft tissue sarcomas, canine myeloid leukemias, and feline intestinal lymphomas as well as specific oral cavity, CNS and stomach cancers. Multi-institutional international collaborative efforts for this special focus issue resulted in articles identifying guidelines for the submission, trimming, margin evaluation, and reporting of surgical biopsy samples; a standardized classification scheme for canine malignant lymphomas; and a proposed 2-tier grading system for canine cutaneous mast cell tumors. The review of canine mammary carcinomas is complemented by articles addressing the development, anatomy, and physiology of the canine mammary gland; the current understanding of the molecular biology of canine mammary neoplasia; and a comparison of the carcinogenesis of canine mammary carcinomas and human breast cancer. The special focus also includes review articles that provide detailed insight into techniques currently applied for the diagnosis of neoplastic diseases (eg, cytoflowmetry) and that highlight the importance of integrating recently gained molecular understanding into the evaluation of neoplastic diseases (eg, evaluation of LOH, COX II, UPS).
These articles represent a close worldwide collaboration of veterinary pathologists and oncologists; furthermore, eight articles in this issue have been reviewed by the Scientific Advisory Committe of the World Small Animal Veterinary Association and were officially endorsed by its Executive Board. The Oncology Committee closely collaborates with the entire veterinary oncology community, and efforts are ongoing to not only disseminate the information provided in this special focus but use this issue as a starting point for future discussions and collaborative research addressing current deficiencies. The articles in this issue provide recommendations based on the contemporary knowledge in the field. The guidance in this special focus needs to be continually reevaluated and revised accordingly as the field of veterinary oncologic pathology continues to progress.
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